News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novaliq GmbH Announces Launch Of A Phase 1 Study Following US And European Patent Approval Of Cyclasol® (Cyclosporin) Eye Drops


4/3/2014 9:15:57 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH today announced the commencement of a Phase 1 study for CyclASol (Cyclosporin solution) following US and European patent approval of the solution for the treatment of dry eye syndrome.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES